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tus, 12 studies with 7262 participants con-
tributed to the findings of hospitalization
and 8 studies including 7755 patients con-
tributed to the data on mortality. Patients
receiving digoxin experienced reduced rates
of hospitalization due to worsening heart
failure (odds ratio [OR]=0.68; 95% confi-
dence interval [CI], 0.61–0.75; number
needed to treat [NNT]=13–17) and less
clinical deterioration (OR=0.31; 95% CI,
0.21–0.43; NNT=3–61). The wide range in
NNT for the reduction in clinical deteriora-
tion reflects varying baseline rates of wors-
ening clinical status found among the 12
■ Evidence summary
A recent Cochrane systematic review sum-
marizes the clinical effects of digoxin when
used for patients with heart failure in nor-
mal sinus rhythm. Thirteen studies includ-
ing 7896 participants, most of whom had
systolic dysfunction, met the criteria for
inclusion. Ninety-four percent of all study
participants came from a single large ran-
domized placebo-controlled trial.3 Because
the studies did not all measure the same out-
comes, subgroup analyses were performed. 
Four studies with 1096 participants
contributed to the findings on clinical sta-
Does digoxin decrease morbidity for 
those in sinus rhythm with heart failure?
In patients with congestive heart failure due 
to systolic dysfunction who are in normal sinus
rhythm, digoxin therapy reduces rates of hospital-
ization, as well as clinical deterioration, defined as
worsening New York Heart Association (NYHA)
classification or an increase in clinical signs and
symptoms (strength of recommendation [SOR]: A,
systematic review of randomized controlled trials
[RCT]).1 These benefits appear to be more 
pronounced for men.2
Patients treated with digoxin are at increased
risk of developing supraventricular dysrhythmias
and second- or third-degree atrioventricular block
(SOR: A, large RCT).3 It is unclear if patients with
diastolic dysfunction experience similar benefits 
or harms (SOR: A, systematic review of RCTs).1
Digoxin has not been shown to have any effect 
on mortality for men with congestive heart failure
in sinus rhythm (SOR: A, systematic review of
RCTs).1 Digoxin use for women may be associated
with an increased risk of mortality2 (SOR: B,
extrapolation from RCT).
E V I D E N C E - B A S E D A N S W E R
Digoxin unlikely to benefit most patients 
with mild heart failure
It is clear that ACE inhibitors, diuretics, and 
beta-blockers should all be the first drugs chosen
for therapy for patients with CHF. They have not
only been shown to improve mortality and reduce
symptoms but they do not carry any of the 
significant risks associated with digoxin toxicity. 
Digoxin is unlikely to benefit patients with
Class I heart failure, as their risk of clinical 
deterioration and hospitalizations are low.
However, for patients who cannot tolerate any of
the first-line drugs or who remain symptomatic
while taking them, digoxin carefully dosed and
monitored is a useful adjunct in practice. 
While it is true that these patients need 
periodic laboratory monitoring, by the time they
require digoxin therapy, their visits for care are
already frequent and they would likely require 
few, if any, additional visits.
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Digoxin should be
used in NYHA
Class II–III
patients in sinus
rhythm who
remain 
symptomatic on
standard therapy
FAST TRACK
studies for patients receiving placebo. The
narrow CI associated with the odds ratio
for reduced rates of clinical deterioration
reflects the fact that the majority of patients
whose clinical status was evaluated as an
outcome came from a single large study, the
DIG trial.3 This trial followed 6800 patients
with NYHA classifications I to III. Ninety-
four percent of patients in this trial were
additionally on angiotensin-converting
enzyme (ACE) inhibitors and 82% were
taking diuretics. Patients were followed for
a mean of 37 months.
A subgroup analysis of 988 patients
with diastolic dysfunction (ejection fraction
>45%) in this study3 suggested no clear
benefits or harms when digoxin was used
in combination with other therapies vs
placebo; however, it did show a positive
trend towards the combined outcome of
reduced hospitalizations and less clinical
deterioration (relative risk [RR]=0.82;
95% CI, 0.63–1.07). Increased rates of
supraventricular dysrhythmias (RR=2.08;
95% CI, 1.44–2.99; number needed to
harm [NNH]=77) and second- and third-
degree heart block were demonstrated for
patients receiving digoxin (RR=2.93; 95%
CI, 1.61–5.34; NNH=125). There was no
difference in mortality between patients
receiving digoxin or those receiving placebo
(OR=0.98; 95% CI, 0.89–1.09).1
A post-hoc subgroup analysis focusing
only on sex-based differences in the DIG
trial suggested women benefit less than men
from reduced hospitalizations: –4.2% (95%
CI, –8.9 to 0.5) vs –8.9% (95% CI, –11.4 to
–6.5) (P=.053).2 When a multivariable
analysis was performed, digoxin use for
women was associated with a higher risk of
mortality (adjusted hazard ratio vs place-
bo=1.23; 95% CI, 1.02–1.47).2
Two randomized controlled withdraw-
al studies, in which patients who were
being treated with digoxin had it discontin-
ued, were also included in the systematic
review. These patients’ clinical outcomes
were then compared with persons who had
continued to receive digoxin for the dura-
tion of the trial. Six parallel design studies,
in which patients taking digoxin underwent
a washout period before being randomized
to either digoxin or placebo, were also
included in the evaluation of digoxin’s
effect on clinical status. Because these
patients had already demonstrated the abil-
ity to tolerate digoxin, these studies may
have been biased in favor of digoxin.4,5
Recommendations from others
The American College of Cardiology/
American Heart Association6 and Heart
Failure Society of America7 guidelines both
recommend that digoxin be used in NYHA
class II–III patients in sinus rhythm who
remain symptomatic on standard therapy
(described as ACE inhibitors, diuretics, and
beta-blockers). Guidelines from the Scottish
Intercollegiate Society,8 the European
Society of Cardiology,9 and the American
Medical Directors Association10 all offer
similar recommendations. ■
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